Tests SHR-A1811 with adebrelimab in HER2-overexpressing lung cancer
Tests SHR-A1811 with adebrelimab in adults with HER2-overexpressing non-squamous lung cancer.
Plain-language title generated from the registry record
Registry title: A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer
Key facts
- Where
- Hangzhou and Shanghai, ChinaSee the 2 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-squamous non-small cell lung cancer that has spread or is advanced, has high HER2, and has not been treated with drugs before.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Locally advanced or metastatic non-squamous non-small cell lung cancer, confirmed by tissue tests. ECOG score of 0 or 1.
- Earlier treatment
- No earlier systemic anticancer treatment for locally advanced or metastatic lung cancer.
- Biomarker or test result
- HER2 overexpression, confirmed by a central laboratory.
Main reasons for not taking part
- Untreated or active cancer spread to the brain or spinal cord, or to the membranes around them
- Another cancer, now or in the past
- Active or past autoimmune disease
- Uncontrolled or severe heart disease
- Active hepatitis B or hepatitis C
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07896005, who can take part
Where in China
- Zhejiang Cancer HospitalHangzhou, ChinaNo longer taking part
- Shanghai Chest HospitalShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Trial code
- NCT07896005
- Record updated
- 26 October 2026
- Original description
This is a randomized, open-label, multicenter, phase 3 clinical study comparing the efficacy and safety of SHR-A1811 in combination with Adebrelimab versus platinum-based doublet chemotherapy in combination with Tislelizumab as first-line treatment in patients with HER2-overexpressing locally advanced or metastatic non-squamous non-small cell lung cancer.Read full original descriptionShow less
A Randomized, Controlled, Open-label, Multicenter Phase III Study of SHR-A1811 Combined With Adebrelimab for the First-line Treatment of Patients With HER2-overexpressing Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
This is a randomized, open-label, multicenter, phase 3 clinical study comparing the efficacy and safety of SHR-A1811 in combination with Adebrelimab versus platinum-based doublet chemotherapy in combination with Tislelizumab as first-line treatment in patients with HER2-overexpressing locally advanced or metastatic non-squamous non-small cell lung cancer.
Inclusion: Able to provide informed consent, willing and able to comply with the scheduled visits, examinations, and other procedural requirements of the treatment; Aged 18-75 years (inclusive) at the time of signing the informed consent form, with no restriction on sex; ECOG score of 0 or 1; Patients with histologically confirmed locally advanced or metastatic non-squamous NSCLC; Participants with HER2 overexpression confirmed by a central laboratory; Have not previously received systemic antitumor therapy for locally advanced or metastatic NSCLC.
Exclusion: Previous or current with other malignancies; Prior antitumor toxicity and/or complications have not recovered to NCI-CTCAE ≤ Grade 1; Currently participating in another clinical study, or the interval between the start of study treatment and the end of the previous clinical study is less than specified period; Participants with active or previous autoimmune diseases; Participants with untreated or active metastasis of central nervous system (CNS) tumors, or a history of meningeal metastasis or current meningeal metastasis; Participants with uncontrolled or severe cardiovascular diseases; Participants with active hepatitis B or hepatitis C.